C4 Therapeutics, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 3.3 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 405.98M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration. It has strategic collaborations F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Betta Pharmaceuticals Co. Ltd., and Merck KGAA. Additionally, it has a collaboration agreement with Roche Holding AG for the development of Degrader-Antibody Conjugates for cancer treatment. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Details
| Name | C4 Therapeutics, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 104 |
| Founded | 2015 |
| Ipo Date | 2020-10-02 |
| Ceo | Andrew Hirsch |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 19.00 |
| Isin | US12529R1077 |
| Cusip | 12529R107 |
| Cik | 1662579 |
| Sic | 2836 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Andrew J. Hirsch M.B.A. | Chief Executive Officer, President and Director |
| Dr. Kenneth C. Anderson M.D., Ph.D. | Co-Founder, Independent Director and Member of Scientific Advisory Board |
| Kendra R. Adams | Principal Accounting Officer, Chief Financial Officer, Head of Corporate Affairs and Treasurer |
| Dr. Leonard M. J. Reyno M.D. | Chief Medical Officer |
| Dr. Nathanael S. Gray Ph.D. | Co-Founder and Member of Scientific Advisory Board |
| Courtney Solberg | Senior Manager of Investor Relations |
| Kelly A. Schick | Chief People Officer |
| Dr. Isabel Chiu Ph.D. | Senior Vice President of Strategic Alliances and Business Development |
| Dr. Christopher Nasveschuk | Senior Vice President of Chemistry |
| Roy Pollock Ph.D. | Senior Vice President of Biological Sciences |
Contact
| Address | 490 Arsenal Way, Suite120, Watertown, Massachusetts 02472, United States |
| Phone | 617 231 0700 |
| Website | https://www.c4therapeutics.com |